IGC Pharma, Inc.: financial analysis
Ratios worked out from 10 fiscal years of IGC Pharma, Inc.'s statements, compared with 665 companies in Biotechnology.
Debt to equity, 2025
0.02×
Biotechnology: 0.26×
IGC Pharma, Inc. scorecard#
Passes 2 of the 8 checks that could be worked out: strongest in financial health (2 of 3), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 26, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median3.9×Price to book 3.9× against Biotechnology's median of 2.9×.
- ✗Price to sales below its peers' median24.9×Price to sales 24.9× against Biotechnology's median of 8.8×.
- ✗Free cash flow yield above 5%-16.8%Free cash flow is -16.8% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 4.92% (2026-11-20).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growthnot known
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitabilitynot known
- –Profitable in the newest yearNo net income on file.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health2 of 3
- ✗Short-term assets cover short-term liabilities0.8×Current ratio 0.83 at the end of fiscal 2025.
- ✓Debt below equity0.0×Debt to equity 0.02 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $1 M at the end of fiscal 2025.
- –Operating income covers interest five timesInterest expense is not on file.
- –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
What the 2025 statements show#
Each line is an observation with its numbers, not a judgement of the company.
Strengths
- More cash than debt: net cash of $1 million.
Worth a look
- Liabilities due within a year exceed current assets (current ratio 0.83).
Profitability#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Gross margin | — | 48.8% | 54.5% | — | — | 74.8% | — | |
| Operating margin | — | -586.6% | -731.3% | — | — | -60.5% | — | |
| Net margin | — | -560.6% | -970.2% | — | — | -68.9% | — | |
| Return on equity | — | -104.3% | -117.0% | -59.3% | -53.0% | -61.0% | — | |
| Return on assets | — | -76.4% | -96.0% | -52.3% | -47.9% | -44.4% | — |
Growth#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | -5.2% | 47.3% | — | — | 15.8% | — | |
| Revenue growth, 3 years a year | — | 47.0% | 14.2% | — | — | 12.9% | — | |
| Revenue growth, 5 years a year | — | -20.8% | -23.5% | — | — | 15.4% | — |
Financial strength#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Debt to equity | 0.02× | 0.02× | 0.02× | 0.01× | 0.01× | 0.26× | 79% | |
| Net debt | $-1 M | $-0 M | $-1 M | $-3 M | $-10 M | $-16 M | 36% | |
| Interest cover | — | — | — | — | — | -22.77× | — | |
| Current ratio | 0.83× | 1.28× | 1.58× | 3.41× | 6.19× | 4.39× | 12% | |
| Equity share of assets | 76.4% | 72.3% | 73.9% | 86.8% | 89.0% | 64.7% | 64% |
Cash#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Free cash flow | — | $-5 M | $-5 M | $-7 M | $-8 M | $-40 M | — | |
| Free cash flow margin | — | -386.6% | -398.5% | — | — | -61.5% | — | |
| Capital spending share of revenue | — | 8.7% | 10.5% | — | — | 1.7% | — |
Efficiency#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Asset turnover | — | 0.14× | 0.10× | — | — | 0.26× | — |
How each figure is worked out#
- Gross margin
- Gross profit as a share of revenue.
- Operating margin
- Operating income as a share of revenue.
- Net margin
- Net income as a share of revenue.
- Return on equity
- Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
- Return on assets
- Net income as a share of total assets (average of the year).
- Revenue growth
- Revenue against the year before.
- Revenue growth, 3 years a year
- The yearly rate that takes revenue of three years earlier to this year's.
- Revenue growth, 5 years a year
- The yearly rate that takes revenue of five years earlier to this year's.
- Debt to equity
- Total debt divided by shareholders' equity. Not given when equity is negative.
- Net debt
- Total debt less cash. Negative means more cash than debt.
- Interest cover
- Operating income divided by the interest paid on debt.
- Current ratio
- Assets due within a year divided by liabilities due within a year.
- Equity share of assets
- Shareholders' equity as a share of total assets.
- Free cash flow
- Cash from operations less capital spending.
- Free cash flow margin
- Free cash flow as a share of revenue.
- Capital spending share of revenue
- Capital spending as a share of revenue.
- Change in share count
- Diluted shares against the year before. Negative: fewer shares.
- Asset turnover
- Revenue divided by total assets (average of the year).